Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Nifekalant Versus Amiodarone in New-Onset Atrial Fibrillation After Cardiac Surgery — Stella

Home/New Onset Atrial Fibrillation/

View on ClinicalTrials.gov

Recruiting

Back to New Onset Atrial Fibrillation trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

China

Beijing Anzhen Hospital, Beijing

Key details

Phase

Large-scale testing

Sponsor

Beijing Anzhen Hospital

Enrollment target

~274 participants

Started

May 2022

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 85 Years

Last updated June 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.